|drug1054||High Flow Nasal Oxygen (HFNO) Wiki||1.00|
|drug2191||Sample collection Wiki||0.71|
|D011024||Pneumonia, Viral NIH||0.13|
|D045169||Severe Acute Respiratory Syndrome NIH||0.05|
|D018352||Coronavirus Infections NIH||0.04|
There is one clinical trial.
The purpose of the COVIDNOCHE trial (HFNO versus CPAP Helmet Evaluation in COVID-19 Pneumonia) is to evaluate the comparative effectiveness of standard care non-invasive respiratory support (helmet CPAP versus HFNO) for acute hypoxemic respiratory failure from COVID-19 pneumonia on ventilator-free days (primary outcome) and other clinical outcomes measured up to 90 days.
Description: VFD is the number of days alive and free of mechanical ventilation in the first 28 days after study enrollment. Death before 28 days will be assigned a VFD equal to 0 to penalize non-survival. In cases of repeated intubation and extubation, periods free from invasive ventilation and lasting at least 24 consecutive hours will be calculated and summed. Timing of intubation and extubation will be captured in hours, and the number of hours a patient received invasive ventilation will be used to calculate duration of ventilation.Measure: Ventilator-Free Days (VFD) Time: 28 days
Description: Days spent in the ICU and hospital after time of enrollmentMeasure: ICU and Hospital Length of Stay Time: 28 days
Description: Incidence and time to intubation in days after the time of enrollmentMeasure: Intubation Time: 28 days
Description: Incidence of RRT after the time of enrollmentMeasure: Renal Replacement Therapy (RRT) Time: 28 days
Description: Death from any cause during after the time of enrollmentMeasure: Mortality Time: 28 days, 90 days